View More Recent Stories
-
JPMorgan is out with its 2025 outlook for biotech stocks
-
H.C. Wainwright Reiterates Buy Rating on Xenon Pharmaceuticals (XENE)
-
Xenon Pharmaceuticals (XENE) PT Raised to $56 at RBC Capital
-
Xenon Pharmaceuticals (XENE) Tops Q3 EPS by 1c
-
Raymond James Resumes Xenon Pharmaceuticals (XENE) at Outperform
-
H.C. Wainwright Starts Xenon Pharmaceuticals (XENE) at Buy
-
Xenon Pharmaceuticals (XENE) Expands Leadership Team with Matthew D. Ronsheim, Ph.D. as COO
-
Xenon Pharmaceuticals (XENE) Files Mixed Shelf
-
Xenon Pharmaceuticals (XENE) Misses Q2 EPS by 5c
-
RBC Capital Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE)

